CLINICAL TRIALS PROFILE FOR HALOPERIDOL DECANOATE

All Clinical Trials for haloperidol decanoate

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00018642 ↗	Quetiapine vs Haloperidol Decanoate for the Long Term Treatment of Schizophrenia and Schizoaffective Disorder	Completed	US Department of Veterans Affairs	N/A	1997-04-01	The purpose of this research study is to determine whether a new drug for schizophrenia is better for the maintenance treatment than a standard drugs currently prescribed. The new medication is called quetiapine and it will be compared with a standard medication called haloperidol decanoate. The study will determine if quetiapine causes fewer problems than haloperidol with side effects such as stiffness and restlessness and whether it costs the VA more or less to treat patients with quetiapine. In addition, blood samples will be collected every three months to determine if certain chemicals in the blood can influence the outcome of the subjects' illness.
NCT00018642 ↗	Quetiapine vs Haloperidol Decanoate for the Long Term Treatment of Schizophrenia and Schizoaffective Disorder	Completed	VA Office of Research and Development	N/A	1997-04-01	The purpose of this research study is to determine whether a new drug for schizophrenia is better for the maintenance treatment than a standard drugs currently prescribed. The new medication is called quetiapine and it will be compared with a standard medication called haloperidol decanoate. The study will determine if quetiapine causes fewer problems than haloperidol with side effects such as stiffness and restlessness and whether it costs the VA more or less to treat patients with quetiapine. In addition, blood samples will be collected every three months to determine if certain chemicals in the blood can influence the outcome of the subjects' illness.
NCT00947375 ↗	Lamictal TM, Haloperidol Decanoate in Schizophrenia	Terminated	Central Mental Clinic for Outpatients of Baku City	Phase 4	2005-01-01	The purpose of this study is to determine the effect of lamotrigine augmentation of Haloperidol decanoate in the treatment of Resistant Schizophrenia predominantly by verbal resistant hallucinosis: A randomized, double-blind, placebo-controlled, study. Nadir A.Aliyev & Zafar N.Aliyev Central Mental Clinic for Outpatients of Baku city of Azerbaijan Republic Abstract: OBJECTIVE: The current paper reports on a double-blind, randomized study of the role of lamotrigine as an augmentation agent to haloperidol decanoate in the treatment of out patient's schizophrenia with verbal resistant hallucinosis.
NCT01136772 ↗	A Comparison of Long-acting Injectable Medications for Schizophrenia	Completed	Duke University	Phase 4	2011-03-01	The purpose of this research study is to compare the "real-world" effectiveness of two FDA-approved and widely used long-acting injectable antipsychotic medications (paliperidone palmitate and haloperidol decanoate) in patients with schizophrenia or schizoaffective disorder who are expected to benefit from the improved medication compliance associated with injectable medications. The goal is to evaluate the effects of the medications on outcomes of importance to patients (relapse, symptoms, adverse effects, functioning) as well as policy makers (all of the above plus costs).
NCT01136772 ↗	A Comparison of Long-acting Injectable Medications for Schizophrenia	Completed	National Institute of Mental Health (NIMH)	Phase 4	2011-03-01	The purpose of this research study is to compare the "real-world" effectiveness of two FDA-approved and widely used long-acting injectable antipsychotic medications (paliperidone palmitate and haloperidol decanoate) in patients with schizophrenia or schizoaffective disorder who are expected to benefit from the improved medication compliance associated with injectable medications. The goal is to evaluate the effects of the medications on outcomes of importance to patients (relapse, symptoms, adverse effects, functioning) as well as policy makers (all of the above plus costs).

Clinical Trial Conditions for haloperidol decanoate

Condition Name

Condition Name for haloperidol decanoate
Intervention	Trials
Schizophrenia	4
Schizoaffective Disorder	2
Schizophrenia and Disorders With Psychotic Features	1
Subsyndromal Delirium	1

Condition MeSH

Condition MeSH for haloperidol decanoate
Intervention	Trials
Schizophrenia	5
Psychotic Disorders	4
Mental Disorders	2
Delirium	2

Clinical Trial Locations for haloperidol decanoate

Trials by Country

Trials by Country for haloperidol decanoate
Location	Trials
United States	20
Tanzania	1
Nigeria	1
Azerbaijan	1

Trials by US State

Trials by US State for haloperidol decanoate
Location	Trials
California	2
Texas	2
Ohio	2
Nebraska	1
Missouri	1

Clinical Trial Progress for haloperidol decanoate

Clinical Trial Phase

Clinical Trial Phase for haloperidol decanoate
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	1
Phase 2	1

Clinical Trial Status

Clinical Trial Status for haloperidol decanoate
Clinical Trial Phase	Trials
Completed	5
Terminated	1
Unknown status	1

Clinical Trial Sponsors for haloperidol decanoate

Sponsor Name

Sponsor Name for haloperidol decanoate
Sponsor	Trials
National Institute of Mental Health (NIMH)	2
Case Western Reserve University	2
University Hospitals Cleveland Medical Center	1

Sponsor Type

Sponsor Type for haloperidol decanoate
Sponsor	Trials
Other	10
NIH	5
U.S. Fed	2